VCAN, expressed highly in hepatitis B virus-induced hepatocellular carcinoma, is a potential biomarker for immune checkpoint inhibitors

doi:10.4251/wjgo.v14.i10.1933

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3416)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-4) series.

Item

Count

PDF

145

WORD

HTML

1774

Figures (1-8)

156

Tables (1-4)

122

Sum=2238

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

247

Download

931

Sum=1178

Oct 15, 2022 (publication date) through Jun 5, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Oncol. Oct 15, 2022; 14(10): 1933-1948
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.1933

Full Size Figure Download Figure

Figure 5 Immunohistochemical staining for VCAN in tumor tissue and adjacent tissue. A: Immunohistochemical results of VCAN in normal liver tissue and liver tumor tissue in the Human Protein Atlas; B: Immunohistochemical results of VCAN in liver tumor tissue and tumor-adjacent tissue from patients.

Citation: Wang MQ, Li YP, Xu M, Tian Y, Wu Y, Zhang X, Shi JJ, Dang SS, Jia XL. VCAN, expressed highly in hepatitis B virus-induced hepatocellular carcinoma, is a potential biomarker for immune checkpoint inhibitors. World J Gastrointest Oncol 2022; 14(10): 1933-1948
URL: https://www.wjgnet.com/1948-5204/full/v14/i10/1933.htm
DOI: https://dx.doi.org/10.4251/wjgo.v14.i10.1933